Reliable and Rapid Testing for COVID-19 with ender MASS

ender diagnostics launches their second CE-certified COVID-19 test, which will enable rapid, and high-volume testing in schools, manufacturing facilities, hospitals, and care homes.

One of the essential elements for the control of COVID-19 is reliable and rapid testing. However, testing capacity is a significant global challenge due to shortages in healthcare services.

Our portfolio company ender diagnostics launches ender MASS, its second CE-marked test to detect SARS-CoV-2, the virus behind the COVID-19 pandemic. With ender MASS, it only takes 30 minutes to diagnose COVID-19. It considerably reduces the workload for medical professionals and laboratories. Moreover, it enables on-site and pop-up labs to operate rapid testing in diverse settings, potentially including travel-related locations.

«Constant rapid and flexible testing is key in controlling the COVID-19 pandemic, and enabling countries and economies around the world to open up and recover.» comments Tim Pfister, CEO of ender diagnostics «ender diagnostics is well placed to make a significant impact to help avoid partial or large-scale lockdowns around the world. » 

PR_enderMASS_EN

 

HEMEX supports the ender team with clinical, regulatory, and marketing services. HEMEX’s regulatory experts will support the CE-certification of the test as an in vitro diagnostic medical device under the European In Vitro Diagnostic Regulation (IVDR). 

Passport to Success!

Cultural diversity celebration at Hemex. We have recently increased our workforce because luckily, we are expanding.

 

“We embrace diversity because in the international environment that we work in, it just feels natural to be a multicultural team.”

– Pascal Winnen, CEO of Hemex.

 

Diversity and inclusion are key words in our modern, globalized world. Several research articles confirm that companies who focus on bringing different people together, improve the quality of teamwork. However, cultural diversity is not just a management trend, it is a type of organizational culture that defines a company. This organization allows all members to pursue their aspirations without being inhibited by gender, race, nationality, disability, age, or sometimes just being a parent. Diversity is the beauty of going to work and being assessed by your achievements, not by other qualities irrelevant to your performance. A multicultural workplace provides a range of opportunities, both for the company and its workers.

At Hemex, we embrace diversity, and we encourage everyone else to do the same. Diversity not only influences our organizational performance but also significantly improves and creates a great working environment.  Having a team made up of different people, each with their own vision, background, education, and origin, binds our team at all levels.

Our current team consists of people from many different countries in the world and we speak more than 20 languages. We strongly believe in gender diversity, which is why 60% of our workforce consists of hard-working women.

We are very proud of the Hemex team. Therefore, over the course of the coming weeks we will be publishing a series of articles on our team members. This will allow you to get to know the great people behind all the hard work we do.

How do you embrace diversity? Tell us!

 

About HEMEX

Hemex was founded as a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. We are now gaining fast recognition, and partly this is because we are transforming the culture by seamlessly bridging the gap between investors and entrepreneurs.

Hemex Organizes Successful Biotech/Pharma Online Pitch Event

Today, Juvabis, Inura Medical, SunRegen Healthcare, and Saverna Therapeutics have pitched their ventures at the HEMEX incubator to an online group of renowned international investors.

 

HEMEX frequently holds pitch events, where selected start-ups get the opportunity to pitch in front of potential investors. Since June, we have been organizing online Pitch Events to ensure safety for all participants. The focus of this morning’s pitch session was for start-ups seeking to revolutionize the fields of antimicrobial resistance, women’s health, neurodegeneration, and autoimmune diseases.

Today’s event kicked off with the start-up Juvabis AG. Sven Hobbie and Marc Creus, CEO and Head of BD at Juvabis respectively, presented their product pipeline which focuses on antimicrobial therapeutic drugs. They have developed a strategic opportunity to solve the problem of antimicrobial resistance (AMR).  Their program is an antibiotic-combination therapy for the treatment of drug-resistant infections in patients with limited treatment options. “We have an extremely robust base, concrete clinical data, and have a solid project which we are ready to push forward with”, Marc Creus tells Hemex after the presentation. “We were busy delivering, we have completed Phase I and now we are ready to start Phase II” added Sven Hobbie. Juvabis aims to develop innovative formulations that can be used to treat chronic, rare, and orphan diseases.

The second start-up pitching at our event was Inura Medical AG. Rafiq Hussain and Vanja Ivancevic, CEO and COO of Inura respectively, presented their innovative idea. Inura has developed an innovative patented urethral suppository for women, using an existing, approved drug with a well-known safety profile. It offers rescue therapy for a highly prevalent and disabling health disorder: overactive bladder syndrome (OAB). “In all my years working as a physician I have seen many women who are suffering from this disease, but the current treatment options do not work for everybody”, Rafiq Hussain tells Hemex, “patients would not hesitate to test another treatment, and we don’t want to give them another pill, so we are offering them a solution with a novel administration route that actually works” adds Vanja. This product facilitates the effective penetration of drugs through the urethral mucosal lining preventing the symptoms of this disease and reducing side effects. 

The third start-up pitching was Sunregen Healthcare AG. Mark Freedman, CEO of SunRegen, presented their innovative treatments for retinitis pigmentosa, a rare ophthalmological neurodegenerative disease. SunRegen has a potent, broad-acting, neuroprotective, neuro-rescuing small molecule that can be dosed orally and crosses the blood-brain barrier. Raw data proves that the compound plays a role in proteostasis and anti-apoptotic pathways, which provides additional rationale for its ability to protect and rescue a whole range of neurological stresses. “As a start-up, we need to find the right partner to help us go to the next stage” Mark explains to Hemex after his presentation, “and if we end up being right, this will make a huge impact and change the lives of people suffering from these neurodegenerative diseases.”

Last but not least, Saverna Therapeutics AG closed our Biotech/Pharma Pitch Event. Kamal Azzaoui, CEO of Saverna Therapeutics, presented their project which focuses on autoimmune diseases. Saverna uses integrated fragment-based screening (FBS) by Nuclear Magnetic Resonance (NMR) in-silico machine learning (ML), and cellular assays for drug discovery. The start-up has discovered a molecule that has shown cellular and in vivo activity, which would be a great candidate for Lupus disease. “We have the first molecule that is targeting the modulators of microRNA and we are proving that this platform works, which has huge potential to revolutionize drug discovery” explains Kamal to the Hemex team after his presentation.

Many thanks to Marc, Sven, Rafiq, Vanja, Mark, and Kamal for introducing us to their unique ideas in the fields of antimicrobial resistance, women’s health, neurodegeneration, and autoimmune diseases. We wish you good luck with your projects!

Are you interested in becoming an early-stage investor in one of these promising start-ups? Would you like to receive a personalized invitation to one of our next sessions?

Or are you interested in learning about how to create a great pitch deck that excites potential investors about your idea?

Then you are in the right place! Contact our start-up coach Franziska Stemmler for more information.

 

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX

Let’s talk about Women’s Health

Women are generally known to suffer from more acute and chronic symptoms and use health services more frequently than men. Recent research highlights significant knowledge gaps in the field of women’s health.

 

“Despite medical advances in healthcare over the past decades, societ­ies are still failing women at key moments in their lives. Too many girls and women are still unable to reach their full potential because of health problems, gender inequalities, and inadequacies in the health system.”

-Dr Margaret Chan, Director-General WHO


In presenting the start-ups below, Hemex hopes to stimulate dialogue and draw attention to the innovative strategies our portfolio companies have developed. These ground-breaking solutions could lead to real improvements in women’s health around the world.

 

MOMM Diagnostics logoMOMM Diagnostics

MOMM Diagnostics is developing a new technology for the early detection of preeclampsia (PE). PE is a life-threatening pregnancy complication that can have devastating effects on the health of the mother and the baby. Every year, there are 75’000 maternal and 500’000 infant deaths because of preeclampsia. It is also a huge economic burden and a rapidly progressive condition. Therefore, early recognition of symptoms could save lives. MOMM Diagnostics is developing a fast and precise test that provides diagnostic certainty, and at the same time reduces healthcare costs. This new technology provides a novel solution to identify preeclampsia, quantifying low-abundant biomarkers from a single drop of blood.

 

Aspivix

Aspivix is developing the next-generation surgical instrument for gentle and modern gynecological procedures. The Intra-Uterine device (IUD) is one of the most cost-effective reversible contraception techniques, but the Tenaculum that is used in this procedure (to grasp and pull the cervix) is very painful and can cause bleeding, lesions, and infections. With Aspivix’s instrument, a gentle vacuum suction-pad is applied on the cervix to steady it during gynecological procedures. The pain is minimized, there is no bleeding, the risk of cross-contamination is eliminated and the whole experience is less traumatic. Moreover, an Aspivix survey showed that 95% of physicians would like a better device to significantly reduce their time and the costs associated with IUD insertion.

 

Inura Medical AG logoInura

Inura Medical is developing an innovative urethral suppository for women with Overactive Bladder syndrome (OAB). This highly prevalent and disabling health disorder has a huge impact on the quality of life of 20% of the female population. For instance, sleep deprivation, fatigue, nocturia, or memory lapses. Unfortunately, around 70-90% of the patients discontinue the available treatments because of their side effects. Inura Medical’s new, patented design suppository facilitates the effective penetration of drugs through the urethral mucosal lining. This new route of administration has greater therapeutic efficacy and there are fewer side effects. Moreover, Inura Medical’s technology will reduce healthcare costs related to the treatment of OAB. Thanks to its partnership with HEMEX, Inura can complete an entire development program until Phase 3 in which the effects of the oral and urethral administration of the drug will be compared.

 

Hemex believes that protecting and promoting women’s health for future generations is very important. We will continue supporting start-ups who have formidable value and innovative ideas. There are many ways you can show your support in the global effort to improve women’s health. If you are someone who is passionate about making a difference and pushing scientific discoveries in women’s health, help us spread the word! If you are an investor interested in the above ideas and products, please contact us!

 

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices, and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups find non-dilutive and dilutive funding. More at HEMEX

Fighting COVID-19 with VirOmics Playground

BigOmics’ platform to win the battle against coronavirus is called VirOmics Playground. It analyzes and visualizes biological data for COVID-19, and it is accessible to everyone!

 

Open data can play a big role in understanding how pandemics works because it provides crucial insights about the patterns behind the data. BigOmics Analytics launched a special edition of their platform at the beginning of the pandemic called VirOmics Playground, dedicated to analyzing COVID-19 data. Since April, more than 5’000 users have visited this platform.

BigOmics Analytics are the creators of Omics Playground, a self-service analytics platform that allows biologists to perform complex analysis and visualization of data. The platform focusses on the interpretation of data, offering highly interactive visualization tools to understand it easily.

BigOmics’ mission is to help scientists visualize and understand their “omics” data, which is an approach that can be used when analyzing complete genetic or molecular profiles of humans and other organisms.

Nowadays, overcoming COVID-19 is one of the world’s top priorities. That is why BigOmics is playing an important role in understanding this disease, one of the biggest challenges in human history to date. VirOmics Playground provides scientists with easy access to an elaborate analysis of biomedical data by giving availability to various samples of previous infectious diseases with coronavirus such as MERS and SARS as well as the current SARS-CoV-2.

On this platform, researchers and specialists can easily and intuitively visualize big amounts of information. The kind of knowledge that could be useful in current studies to identify, among other things, potential drugs with antiviral activities, or genetic indicators for the development of vaccines.

BigOmics Analytics was founded at the end of 2018 as a spin-off of the Institute of Oncology Research in the southern part of Switzerland. A year before, they had won third prize in the StartCup Ticino competition for the best start-up idea with their vision to democratize big data analysis in life science research. In June they signed a partnership agreement with BC Platforms, and it has been selected for two accelerator programs in Europe (InvestHorizon) and the US (Alchemist)

 

Hemex is proud to support BigOmics. The start-up is currently raising money for its Seed Round. Are you also interested in contributing to a world of Big Data that is accessible to everyone? For more information, contact Pascal Winnen, our CEO, and he can explain to you all the benefits of democratizing omics data.

 

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at HEMEX

The Weaker Sex?

Hemex is particularly inspired by the hard-working women who push boundaries to create innovative healthcare solutions. Dedicated and powerful female leaders enrich the diversity of our Swiss start-up portfolio. Today, we would like to introduce five remarkable female role models to you.

Becoming a successful entrepreneur / leader is not easy, especially for women. Two common challenges female leaders face in the academic and scientific world are sometimes referred to as the “glass ceiling” (the invisible barrier that keeps women from rising) and the “leaky pipeline” phenomenon (the way that women disappear from some career pathways).

The process of building a new company from scratch is challenging, yet incredibly rewarding when dreams materialize, and new discoveries improve the lives of people around the world. Research shows that companies that embrace team gender diversity are stronger and more efficient at tackling external and internal challenges. Therefore, we have decided to dedicate this post to our fast-growing list of impressive female leaders in our portfolio companies.

 

Iselin Frøybu

Iselin is Co-founder and COO at EMOVO CARE. She is a hardware engineer who studied Mechanical Engineering at Penn State University and has a Master’s degree from EPFL. Iselin turned into a business developer with a passion for developing meaningful technologies. She says that the question is no longer whether we can make something, but rather whether we should. She also likes to fight stereotypes and entropy. Iselin is an inspiring woman, who has played a crucial role in the company’s success. Her work never ceases to amaze us. With Emovo Care, Iselin is on a mission to significantly improve quality of life for stroke survivors.

 

Özge Karakas

Özge is Co-Founder and COO at Hi-D IMAGING. She is an experienced scientist, entrepreneur, and a postdoctoral researcher at ETH Zurich. Özge has over 10 years of experience in thermodynamics and fluid dynamic models. On top of this, she has completed a minor degree in Computer Science and Engineering. Özge has been instrumental in the company’s creation, writing the business plan and managing company finances.

 


Ronja Bruhn

Ronja is CEO and Co-Founder of STIMIT. She is a medical engineer with an MBA in Innovation & Entrepreneurship. With 12 years of experience in R&D industry projects and an EMEA product launch, Ronja has impressive experience when it comes to bringing healthcare products to market. Her hard work has demonstrated that STIMIT provides added clinical benefits to patients. With STIMIT, Ronja works on a noninvasive solution for patients lacking natural breathing function. STIMIT’s vision is to empower sedated ICU patients to breathe, creating natural breath instead of pumping air into the lungs.

 

Danuta Cichocka

Danuta is the CEO and Co-Founder of RESISTELL. She is a microbiologist passionately driven by life science, innovation, and self-development. She finished her PhD at the UFZ Leipzig, completed the Executive MBA program at EPFL, and obtained a CAS in Management of Biotech, Medtech & Pharma Ventures. Her key strength is being able to bridge the gap between research and business. Her ability to translate a complex problem into manageable challenges is admirable. Being able to not only see the big picture but knowing how to communicate it is a valuable strength that we truly appreciate at Hemex. With Resistell, Danuta works on the world’s fastest antibiogram to save lives by finding the right antibiotic in time and combat antibiotic resistance.

 

Marija Plodinec

Marija is CEO and Co-Founder of ARTIDIS. She believes in the potential of their technology to transform a cancer patient’s journey (and so do we at HEMEX). Marija studied physics at the University of Zagreb and completed her doctorate from the Maurice Müller Institute at the Biozentrum of the University of Basel. She is also a member of several international organizations and a Senior Principal Scientist at the University Hospital Basel. She is an energic source of inspiration in the field of physical sciences in oncology. At Artidis, Marija is dedicated to developing a rapid diagnostic technique to detect cancer.

 

Still think women are the “Weaker Sex”? Think again and embrace diversity – as we do here at Hemex!

Interview with Scailyte’s CEO Peter Nestorov

In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”.

As a founder and CEO, Peter faces a lot of challenges in his daily activities, but he always had the interest to be involved in multiple initiatives. “I managed a student NGO during my studies and organized numerous international meetings, so I had some basis when I decided to become the CEO of a startup”. It is exactly this transition to become the CEO of a company like Scailyte that has given Peter the skills to succeed as an entrepreneur.

The path of an entrepreneur is sometimes harsh. Peter states that surrounding yourself with a smart and experienced team is necessary. “What helps me a lot is the support and coaching I receive from more experienced entrepreneurs and experts from various industries”.

We at Hemex are thrilled to work with vibrant start-ups like Scailyte. Our slogan “Your Ideas. Our Expertise. One Goal.” reflects that we support the start-ups to achieve a common goal, to efficiently combine the smart ideas of entrepreneurs like Peter Nestorov, with our bench-to-market expertise in order to improve patients’ lives.

You can find the full interview here.

Scailyte is a data-driven biomarker discovery company, that detects complex disease patterns from single-cell data at the onset of disease. Only a small fraction of cells is abnormal, and the changes of the molecular profile are subtle. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018.

Hemex is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its focus to bring innovative drugs, medical devices, and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding.

At Hemex we are proud to have recognized Scailyte’s potential and to be part of their successful journey.

Online Pitch Event @ HEMEX

Five Promising Swiss Start-ups Pitched their Ventures from the HEMEX Incubator to Renowned Swiss and US Investors 

 

Emovo Care SA is an EPFL spin-off, founded in 2020, developing Emovo Hand – the world’s 1st portable hand orthosis to support care-at-home after a stroke. Based on patent-protected soft robotics technology developed at EPFL, the product provides a natural sensation of moving the hand to hemiparetic stroke patients – to practice functional, comfortable, and intensive exercises at home. Compared to existing solutions, Emovo Hand’s has the additional feature of actively opening the hand – an indispensable function for stroke survivors. Emovo’s connected solution will enable to motivate and measure patients’ progress – to maximize the outcome of care and create value for patients, clinicians, and health insurances.

 

ASPIVIX SA is a medical technology company specializing in Women’s Health, co-founded by three seasoned experts: a gynecologist, a medtech engineer, and a business leader. CAREVIX™ is a next-generation atraumatic cervical device used in gynecological procedures requiring uterus access. A proprietary vacuum & suction-based technology is used to reduce pain, eliminate bleeding, and tissue tear endured by 80 million women worldwide every year during common procedures such as intra-uterine device insertion and hysteroscopy.

 

HexagonFab Ltd is a Zurich-based startup, founded in 2018. HexagonFab’s team has developed a new generation of biosensors for rapid and highly sensitive analysis of biomolecules like antibodies, proteins, and small molecules. This award-winning technology, based on graphene nanomaterial, allows pharmaceutical researchers and production staff to monitor biomolecule quality directly at the production line, which offers a $1B market opportunity.

 

STIMIT AG is a medical device start-up founded in 2018 based on a clinical need identified by intensive care and healthcare professionals. A fully functional prototype and physiological proof-of-concept has been developed by the team. STIMIT is using non-invasive technology to stimulate the core breathing muscle (diaphragm) of ventilated intensive care patients. Fifty percent of these patients have significantly weakened breathing muscles after a few days of ventilation, which leads to difficult recovery and oftentimes death. 

 

PreComb Therapeutics AG, founded in 2018, is developing the first point-of-care solution for clinically relevant drug testing, leveraging patient-derived 3D microtissues for drug development and precision medicine. The 3D3 technology has been tailored to meet the critical requirements for the industrialization of patient-specific functional drug testing. 3D microtumors that reflect the original cell composition and microenvironment are produced from small amounts of tissue to generate a high number of drug efficacy data. 

 

Interested in becoming an early-stage investor in one of these promising start-ups or do you want to be kept informed about their progress and future funding rounds / pitch events?

Please contact our start-up scout Franziska Stemmler at +41 61 927 28 02 or franziska.stemmler@hemex.ch

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at https://hemex.eu/

Scailyte is finalist for Nature Research Spinoff Prize!

Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize.

The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies. The Spinoff Prize aims to encourage and provide visibility to academic entrepreneurs and their startups. The judging panel looks for spinoffs that translate original, high-quality scientific research into products and services that address market problems and are well positioned to make a positive impact on society. The focus of this year’s award involves four categories: pharmaceuticals, agriculture, chemicals, and digital technologies. We are particularly proud that Scailyte has reached the finals of this fantastic showcase!

Scailyte is a data-driven biomarker discovery company, that detects complex disease patterns from single-cell data at the onset of disease. Only a small fraction of cells is abnormal, and the changes of the molecular profile are subtle. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018.

Hemex is a privately-owned swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its focus to bring innovative drugs, medical devices, and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding.

At Hemex we are proud to have recognized Scailyte’s potential and to be part of their successful journey.

How Animal Health Innovation Enabled a Rapid and Reliable SARS-CoV-2 Diagnostic Test Kit

In the battle of fighting against COVID-19, a rapid test is crucial to understand the spread of the pandemic.

The Swiss start-up LiVET that originally developed diagnostic tests for respiratory diseases in horses has accelerated their platforms to detect COVID-19 in human samples, establishing a newly incorporated company ender diagnostics ag. Undeniably, ender is a fascinating example of how health developments can be transferred from animal health technology into human health. ender’s isothermal technology utilizes a single temperature for all the steps providing a dramatic decrease of detection time when comparing to the gold standard polymerase-chain-reaction (PCR). In addition, its 30-minute turnover platform can support a relatively small sample size, no need for waiting for a large sample size in a batch. Thus, it is flexible and efficient to operate in laboratories.

Besides the currently sold CE-marked detection kit ender LAB, the company is developing its new outstanding platforms, ender MAS and ender MOBILE, which provide much simplified steps for the sample handling and for point-of-care purpose.

As of 25 June, the cost of all coronavirus tests, including coronavirus and antibody tests, will be covered by the Swiss federal government, implying that people would be more willing to get themselves tested (source: The Federal Council). The Federal Office of Public Health (FOPH) has encouraged people to participate in prevention efforts by installing the SwissCovid app, a proximity tracing system to help in contact tracing and informing people who have spent a certain time with someone who tested positive for coronavirus.

Hand holding mobile with geoHealthApp for COVID-19 tracking

A similar app has been already launched in Switzerland in April by GeoHealthApp, a german start-up supported by HEMEX.

In an estimated 8,000 tests per day carried out in Switzerland, the need for tests is still increasing (source: thelocal.ch). A prediction model of Prof. Dirk Mohr at ETH Zurich suggests that the second pandemic wave would develop more slowly but potentially more deadly (source: Swissinfo). The good news is that it would not overload the Swiss healthcare capacity and we could better prepare in testing and tracing the population. There is no doubt that start-ups such as ender diagnostics play a pivotal role in this battle of COVID-19.

In summary, with the increased availability of advanced testing kits and tracing apps, we can now better monitor the current pandemic status in Switzerland and respond rapidly in order to prevent catastrophic local outbreaks.

HEMEX supports LiVET, ender diagnostics, and GeoHealthApp with clinical, regulatory and market access services.

For more information, see Swissinfo.ch.